- TScan Therapeutics Announces Updates to its Board of Directors
- TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
- TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
- TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- TScan Therapeutics Announces Closing of Upsized Public Offering
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
More ▼
Key statistics
On Wednesday, TScan Therapeutics Inc (TCRX:NMQ) closed at 5.86, -39.53% below its 52-week high of 9.69, set on May 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.73 |
---|---|
High | 6.12 |
Low | 5.63 |
Bid | 5.00 |
Offer | 6.70 |
Previous close | 5.73 |
Average volume | 1.13m |
---|---|
Shares outstanding | 52.86m |
Free float | 48.17m |
P/E (TTM) | -- |
Market cap | 309.78m USD |
EPS (TTM) | -1.28 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼